Anterior cruciate ligament (ACL) and multiligament knee (MLK) injuries increase the risk of development of knee osteoarthritis and eventual need for total knee arthroplasty (TKA). There are limited data regarding implant use and outcomes in these patients. The aim of this study was to compare the use of constrained implants and outcomes among patients undergoing TKA with a history of prior knee ligament reconstruction (PKLR) Patients with a history of ACL or MLK reconstruction who underwent TKA between 2007 and 2017 were identified in a single-institution registry. There were 223 patients who met inclusion criteria (188 ACL reconstruction patients, 35 MLK reconstruction patients). A matched cohort, also of 223 patients, was identified based on patient age, body mass index (BMI), sex, and year of surgery. There were 144 male patients and 79 female patients in both cohorts. Mean age at the time of TKA was 57.2 years (31 to 88). Mean BMI was 29.7 kg/m2 (19.5 to 55.7).Aims
Patients and Methods
Analysis of the morphology of the distal femur, and by extension
of the femoral components in total knee arthroplasty (TKA), has
largely been related to the aspect ratio, which represents the width
of the femur. Little is known about variations in trapezoidicity
(i.e. whether the femur is more rectangular or more trapezoidal).
This study aimed to quantify additional morphological characteristics
of the distal femur and identify anatomical features associated
with higher risks of over- or under-sizing of components in TKA. We analysed the shape of 114 arthritic knees at the time of primary
TKA using the pre-operative CT scans. The aspect ratio and trapezoidicity
ratio were quantified, and the post-operative prosthetic overhang
was calculated. We compared the morphological characteristics with
those of 12 TKA models.Aims
Methods
The need to demonstrate probity and fair market competition has increased scrutiny of the relationships between orthopaedic surgeons and the industry that supplies them with their tools and devices. Investigations and judgements from the US Department of Justice and the introduction of the AdvaMed and Eucomed codes have defined new boundaries for interactions between these groups. This article summarises the current interplay between orthopaedic surgeons and industry, and provides recommendations for the future.
